Hypereosinophilic syndrome (HES) is a very uncommon disease, where a specific type of blood cells called eosinophils are overproduced for prolonged periods of time that results in high blood eosinophil levels and may cause damage to different organs. Little is known about this disease and the people who are suffering from it, and it is for this reason we would like to investigate how many people are affected by this condition in the UK using routinely collected health information from the Clinical Practice Research Datalink. We will look at the number of people who have this disease in the database from 2010-2018, and we will calculate the rate of new cases per calendar year. We will also describe them by their age and gender. If there is enough information available for these patients affected by HES, we will describe the most common illnesses that they have in addition to HES and the most common medications that they are using.
Hypereosinophilic syndrome (HES) is a very rare disease, characterised by a marked eosinophilia sustained over time that may cause organ damage and/or dysfunction. Reliable estimates of the incidence and prevalence of this disease are not readily available, and there is scarce information about the patients who are suffering from it. This study aims to investigate the burden of disease of HES in the UK, using routinely collected health information from the Clinical Practice Research Datalink (CPRD) and characterise those patients according to demographics, common co-morbidities and medications. During the study period, from 2010 to 2018, we will estimate incidence rates and prevalence of HES per calendar year. Then, we will describe demographic characteristics of these patients. Lastly, we will describe the most frequently recorded co-morbidities and the most frequently prescribed medications in the year before the first recorded HES diagnosis and in the year after.
Incidence of Hypereosinophilic syndrome (HES)
- Prevalence of Hypereosinophilic syndrome (HES)
Read code=D403500; Description: Hypereosinophilic syndrome
Melissa Van Dyke - Chief Investigator - GSK
Gema Requena - Corresponding Applicant - GlaxoSmithKline Services Unlimited (UK)
Daniel Gibbons - Collaborator - GlaxoSmithKline Research & Development Limited (UK)
John Logie - Collaborator - GlaxoSmithKline Research & Development Limited (UK)
Jolyon Fairburn-Beech - Collaborator - GSK